Britain was on course to secure another 60million Covid jabs last night after the latest UK-backed vaccine cleared a crucial hurdle. US biotech firm Novavax announced its vaccine had successfully completed its phase three clinical trials in the UK, paving the way for regulators to give final approval in the coming weeks. Under a deal with the Government, 60million doses of the vaccine will be produced on Teesside for use in this country, in what could prove to be another triumph for Britain’s world-leading vaccine programme. Novavax last night said the trials had shown its vaccine was 89.3 per cent effective. The trial is the first to be completed since the emergence of the new variant of the disease in Kent. Preliminary analysis suggests the vaccine was 85.6 per cent effective against this mutation. The two-shot vaccine still requires final approval from the UK’s Medicines and Healthcare products Regulatory Agency. But Whitehall sources said that, if the regulatory process goes smoothly, the jabs could start coming on stream this summer, allowing a huge acceleration in the drive to inoculate all adults by the end of September. Last night, Prime Minister Boris Johnson tweeted: ‘Good news that the Novavax vaccine has proved… Read full this story
- FANTASY NASCAR PREVIEW: Coke Zero 400 drivers to start
- Trisha Goddard, 61, reveals she had fillers after her face 'fell in' as a result of chemotherapy during cancer battle
- NFL Week 11 rundown
- The Coen Bros. Game – Baseball Style
- Hawks guard Kyle Korver on pace for all-time great shooting season
- Should the Giants use Madison Bumgarner in relief in Game 3?
- RotoWire NFL East Coast Offense 121213
Britain on course to produce another 60million Covid vaccines as UK-based Novavax jab PASSES phase three trial with stunning 90% success rate (including quashing 86% of infections by mutant Kent strain that's ravaged the nation) have 262 words, post on www.dailymail.co.uk at January 28, 2021. This is cached page on Vietnam Colors. If you want remove this page, please contact us.